Amicus Therapeutics, INC 10-Q quarterly reports

Amicus Therapeutics, Inc. reported a significant increase in net product sales and a swing to net income for the third quarter, while substantially reducing its net loss for the first nine months of 2025.

Amicus Therapeutics has entered into an exclusive U.S. licensing agreement for Dimerix's Phase 3 FSGS drug DMX-200, while reporting significant revenue growth for its existing Fabry and Pompe disease therapies.

Amicus Therapeutics' Q1 2025 results show revenue growth driven by Galafold and Pombiliti + Opfolda, alongside a strategic licensing agreement for DMX-200.

Amicus Therapeutics saw a significant increase in revenue during the third quarter of 2024, primarily due to the continued growth of Galafold and the launch of Pombiliti + Opfolda.

Amicus Therapeutics saw a revenue increase in the second quarter of 2024, driven by strong sales of Galafold and the launch of Pombiliti + Opfolda, while also managing operating expenses.

Amicus Therapeutics' first quarter 2024 results show increased revenue driven by growth in Galafold sales and the launch of Pombiliti + Opfolda.